BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, Gordon SC, Harrison SA, Kremer AE, Mayo MJ, Thuluvath PJ, Levy C, Swain MG, Neff GW, Sheridan DA, Stanca CM, Berg CP, Goel A, Shiffman ML, Vierling JM, Boudes P, Steinberg A, Choi YJ, McWherter CA. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol 2022:S0168-8278(22)00187-8. [PMID: 35367282 DOI: 10.1016/j.jhep.2022.02.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mishra AK, Singh SP. Seladelpar in patients with primary biliary cholangitis: Need a closer look! J Hepatol 2022:S0168-8278(22)00315-4. [PMID: 35594993 DOI: 10.1016/j.jhep.2022.04.039] [Reference Citation Analysis]
2 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022;76:1263-78. [PMID: 35589249 DOI: 10.1016/j.jhep.2022.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]